| Host: |
Rabbit |
| Applications: |
ELISA |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Clonality: |
Monoclonal |
| Clone ID: |
SRM |
| Conjugation: |
HRP |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.09% Sodium Azide, 0.05% BSA, 50% Glycerol, pH 7.3. |
| Purification: |
Affinity purification |
| Concentration: |
Lot specific |
| Dilution Range: |
ELISA: 1:5000-1:10000 |
| Immunogen Region: |
50-388 aa |
| Specificity: |
Recombinant fusion protein containing a sequence corresponding to amino acids 50-388 of mouse IgE. (AAZ05128.1). |
| Immunogen Sequence: |
FNESRTILVRPVNITEPTLE LLHSSCDPNAFHSTIQLYCF IYGHILNDVSVSWLMDDREI TDTLAQTVLIKEEGKLASTC SKLNITEQQWMSESTFTCKV TSQGVDYLAHTRRCPDHEPR GVITYLIPPSPLDLYQNGAP KLTCLVVDLESEKNVNVTWN QEKKTSVSASQWYTKHHNNA TTSITSILPVVAKDWIEGYG YQCIVDHPDFPKPIVRSITK TPGQRSAPEVYVFPPPEEE |
| Background | Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens 1, 2. The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V- (D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
